Professional
Added to YB: 2024-05-21
Pitch date: 2024-05-15
ADPT [bullish]
Adaptive Biotechnologies Corporation
+300%
current return
Author Info
No bio for this author
Company Info
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.
Market Cap
$2.1B
Pitch Price
$3.86
Price Target
N/A
Dividend
N/A
EV/EBITDA
-46.83
P/E
-25.97
EV/Sales
8.29
Sector
Life Sciences Tools and Services
Category
value
Aristotle Capital Focus Growth Portfolio Holding: Adaptive Biotechnologies Corporation
ADPT: Adaptive Bio to keep MRD diagnostics & immune medicine businesses after strategic review, seeing more value in MRD once profitable. Targets EBITDA breakeven in late 2025, cash flow breakeven in 2026. Q1 revenue beat consensus by ~9%. Low valuation with strong potential remains.
Read full article (1 min)